DAIICHI SANKYO, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $79B
- Website
- http://daiichisankyo.us
Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke
- First Posted Date
- 2014-10-08
- Last Posted Date
- 2015-10-20
- Lead Sponsor
- Daiichi Sankyo
- Registration Number
- NCT02258880
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
- First Posted Date
- 2014-09-09
- Last Posted Date
- 2020-07-23
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 2485
- Registration Number
- NCT02234583
Multiple Dose Study of DS-1971a
- First Posted Date
- 2014-07-15
- Last Posted Date
- 2018-12-24
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 32
- Registration Number
- NCT02190058
- Locations
- 🇬🇧
Hammersmith Medicines Research Ltd., London, United Kingdom
Treatment of Pain Associated With Fibromyalgia
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-07-11
- Last Posted Date
- 2020-11-09
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 1301
- Registration Number
- NCT02187471
Treatment of Pain Associated With Fibromyalgia
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-07-10
- Last Posted Date
- 2020-11-09
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 1270
- Registration Number
- NCT02187159
Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic Impairment
- First Posted Date
- 2014-05-30
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 29
- Registration Number
- NCT02150733
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
Treatment of Pain Associated With Fibromyalgia
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-05-23
- Last Posted Date
- 2020-11-09
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 1293
- Registration Number
- NCT02146430
Multiple Ascending Dose Study of DS-1093 in Healthy Subjects
- First Posted Date
- 2014-05-20
- Last Posted Date
- 2018-12-24
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 31
- Registration Number
- NCT02142400
- Locations
- 🇬🇧
Hammersmith Medicines Research Ltd, London, United Kingdom
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2014-05-08
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 145
- Registration Number
- NCT02134015
Single Ascending Dose Study Using DS-1971 to Assess Safety, Tolerability, and Pharmacokinetics in Healthy Participants.
- First Posted Date
- 2014-04-08
- Last Posted Date
- 2018-12-24
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 64
- Registration Number
- NCT02107885
- Locations
- 🇬🇧
Hammersmith Medicines Research Ltd., London, United Kingdom
© Copyright 2024. All Rights Reserved by MedPath